Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.

摘要: Background:  The Heart Outcomes Prevention Evaluation (HOPE) study has demonstrated that ramipril 10 mg/day for 5 years in an at-risk population results clinically and statistically significant reductions the occurrence of cardiovascular death, myocardial infarction (MI), stroke revascularization procedures. likely impact intervention Australia, terms number potential events avoided cost per life-year saved, previously not been determined. Aims:  To assess clinical economic impacts use daily Australian popu­lation from perspective public health-care budget. Methods: benefits were calculated endpoints used trial, which converted to ‘number needed treat’. These then applied population, was determined nationally relevant statistics. result this calculation is Australia. The established by undertaking incremental cost-effectiveness analysis. model considered costs (and offsets) arising therapy 5 years. Life-years saved calculating difference total years survived between control arms study. Net divided life-years reported dollars as effectiveness. Results:  over a 5-year period expressed comprised approximately: 9188 strokes; 14 658 MI; 14 317 procedures; 12 534 cardiovascular-related deaths, nationally. analysis showed estimated be $A17 214. Conclusion:  could prevent many thousands events, including deaths. compares favourably other health care interventions. (Intern Med J 2003; 33: 414−419)